Research analysts at Leerink Partners initiated coverage on shares of Shattuck Labs (NASDAQ:STTK – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $4.00 price target on the stock. Leerink Partners’ target price suggests a potential upside of 236.13% from the stock’s current price.
Shattuck Labs Trading Down 1.7 %
NASDAQ:STTK opened at $1.19 on Monday. The stock has a market capitalization of $56.81 million, a P/E ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1 year low of $0.94 and a 1 year high of $11.76. The firm has a 50 day moving average of $1.25 and a 200-day moving average of $1.63.
Institutional Trading of Shattuck Labs
Hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. lifted its position in Shattuck Labs by 61.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock worth $5,657,000 after buying an additional 1,775,000 shares in the last quarter. 683 Capital Management LLC acquired a new position in Shattuck Labs during the 4th quarter worth $1,270,000. Prosight Management LP boosted its position in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after buying an additional 873,409 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at $624,000. Finally, Bank of America Corp DE lifted its stake in shares of Shattuck Labs by 135.0% during the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock valued at $226,000 after acquiring an additional 107,491 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.
Shattuck Labs Company Profile
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Stories
- Five stocks we like better than Shattuck Labs
- Find and Profitably Trade Stocks at 52-Week Lows
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- Dividend Capture Strategy: What You Need to Know
- 3 Unique and Dominant Consumer Staples ETF Plays
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
